Keywords: Magnetization Transfer, Muscle, 3D DEXA, body composition, obesity, Ozempic
Motivation: Fatty infiltration in skeletal muscles impairs muscle function and health. Non-invasive imaging techniques are crucial for assessing changes in muscle composition to evaluate treatments.
Goal(s): This study aimed to evaluate the impact of Semaglutide, a GLP-1 agonist, on muscle fat and lean tissue composition in a mouse model of obesity induced by a high-fat diet (HFD).
Approach: Using DEXA, CT, and MRI (with Dixon and magnetization transfer methods), researchers quantified muscle composition changes between Semaglutide-treated and control groups.
Results: Semaglutide increased lean tissue and reduced fat in obese mice, supporting MRI as an effective tool for tracking treatment responses in muscle composition.
Impact: This study highlights an advanced MRI protocol's potential for precisely assessing body composition, showing that Semaglutide improves muscle health by increasing lean tissue and reducing fat. This non-invasive imaging approach could significantly enhance monitoring in metabolic health interventions.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords